Probiodrug´s meeting of the Scientific Advisory Board highlighted programs in metabolic and neuronal disorders.

Probiodrug AG Reported on the Results of its Clinical Phase IIa Trial with the DPIV Inhibitor P93/01 in Type 2 Diabetes and its Patent Licensing Programs
Update on Probiodrug’s Patents